IPN.PA
Price:
$111.7
Market Cap:
$9.23B
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and a...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2005-12-07
Stock Exchange
EURONEXT
Ticker
IPN.PA
According to Ipsen S.A.’s latest financial reports and current stock price. The company's current PE Ratio is 14.05. This represents a change of 54.13% compared to the average of 9.12 of the last 4 quarters.
The mean historical PE Ratio of Ipsen S.A. over the last ten years is 5.78. The current 14.05 PE Ratio has changed 24.19% with respect to the historical average. Over the past ten years (40 quarters), IPN.PA's PE Ratio was at its highest in in the March 2011 quarter at 38.96. The PE Ratio was at its lowest in in the December 2019 quarter at -6.06.
Average
5.78
Median
18.52
Minimum
-119.57
Maximum
30.92
Discovering the peaks and valleys of Ipsen S.A. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 24.03%
Maximum Annual PE Ratio = 30.92
Minimum Annual Increase = -595.24%
Minimum Annual PE Ratio = -119.57
Year | PE Ratio | Change |
---|---|---|
2023 | 13.96 | 8.47% |
2022 | 12.87 | 24.03% |
2021 | 10.38 | 0.43% |
2020 | 10.33 | -108.64% |
2019 | -119.57 | -595.24% |
2018 | 24.14 | -21.92% |
2017 | 30.92 | 22.93% |
2016 | 25.15 | -5.32% |
2015 | 26.57 | 15.16% |
2014 | 23.07 | 22.92% |
The current PE Ratio of Ipsen S.A. (IPN.PA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
12.41
5-year avg
-14.40
10-year avg
5.78
Ipsen S.A.’s PE Ratio is less than bioMérieux S.A. (29.50), less than Eurofins Scientific SE (21.20), less than Sartorius Stedim Biotech S.A. (109.86), less than Arkema S.A. (16.84), greater than SEB SA (12.97),
Company | PE Ratio | Market cap |
---|---|---|
29.50 | $12.13B | |
21.20 | $8.75B | |
109.86 | $18.41B | |
16.84 | $6.11B | |
12.97 | $5.26B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ipsen S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Ipsen S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Ipsen S.A.'s PE Ratio?
How is the PE Ratio calculated for Ipsen S.A. (IPN.PA)?
What is the highest PE Ratio for Ipsen S.A. (IPN.PA)?
What is the 3-year average PE Ratio for Ipsen S.A. (IPN.PA)?
What is the 5-year average PE Ratio for Ipsen S.A. (IPN.PA)?
How does the current PE Ratio for Ipsen S.A. (IPN.PA) compare to its historical average?